Moleculin Biotech, Inc., a clinical drug development company founded in July 2015 in Delaware, focuses on the development of anti-cancer drugs, mainly in cooperation with the M.D. Anderson Cancer Center of the University of Texas. The company's main drug is the lipid anamycin, which is used to treat relapsed or acute leukemia. In addition to two other drugs under development, one is WP1066, which mainly controls key transcriptional regulatory factors involved in cancer; the other is WP1122, which mainly affects the metabolic process of cancer cells through molecular targets. 

MBRX

MBRX